{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.10","upperLimit":"6.70","value":"6.00"},{"groupId":"OG001","lowerLimit":"2.00","upperLimit":"6.60","value":"5.10"},{"groupId":"OG002","lowerLimit":"2.10","upperLimit":"6.00","value":"4.00"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"6.70","value":"3.95"},{"groupId":"OG004","lowerLimit":"5.80","upperLimit":"6.10","value":"5.90"},{"groupId":"OG005","lowerLimit":"4.00","upperLimit":"6.10","value":"6.00"},{"groupId":"OG006","lowerLimit":"2.00","upperLimit":"2.40","value":"2.20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Characterize single and multiple-dose PK of LDK378 in pediatric patients. Tmax: The time to reach maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Participants in the fasted group who took 300 mg of ceritinib","id":"OG000","title":"Fasted: Ceritinib 300 mg/m2"},{"description":"Participants in the fasted group who took 450 mg of ceritinib","id":"OG001","title":"Fasted: Ceritinib 450 mg/m2"},{"description":"Participants in the fasted group who took 510 mg of ceritinib","id":"OG002","title":"Fasted: Ceritinib 510 mg/m2"},{"description":"Participants in the fasted group who took 560 mg of ceritinib","id":"OG003","title":"Fasted: Ceritinib 560 mg/m2"},{"description":"Participants in the fed group who took 320 mg of ceritinib","id":"OG004","title":"Fed: Ceritinib 320 mg/m2"},{"description":"Participants in the fed group who took 400 mg of ceritinib","id":"OG005","title":"Fed: Ceritinib 400 mg/m2"},{"description":"Participants in the fed group who took 500 mg of ceritinib","id":"OG006","title":"Fed: Ceritinib 500 mg/m2"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set (PAS) consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"0hr pre-dose, 2, 4, 6 & 24hrs post-dose","title":"PK Parameter: Tmax in Cycle 2 Day 1 - Dose Escalation Phase (Single Dose)","type":"SECONDARY","unitOfMeasure":"hour (hr)"}